Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults

Podobne zapisy

• Single-Dose Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor, in HIV-Infected Children
  od: Yogev, Ram, i wsp.
  Wydane: (2005)
• Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro
  od: Drusano, G. L., i wsp.
  Wydane: (1998)
• Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease Inhibitors
  od: Schmidt, Barbara, i wsp.
  Wydane: (2000)
• Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
  od: Sadler, Brian M., i wsp.
  Wydane: (2001)
• Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir
  od: Sadler, Brian M., i wsp.
  Wydane: (2001)